Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of luspatercept in transfusion-dependent adult beta-thalassemia patients in China
CTR20222419Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Jan 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept in beta thalassemia, hemoglobin E beta thalassemia (HbE/β-thal), sponsored by Celgene Corporation. Started Jan 2023; status: active.
02
Drugs
luspatercept
03
Conditions
beta thalassemiahemoglobin E beta thalassemia (HbE/β-thal)
Beyond the preview
Go deeper on CTR20222419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222419.